Der Kaninchen Polyklonal Anti-LRRK2-Antikörper wurde für WB, ELISA und IF validiert. Er ist geeignet, LRRK2 in Proben von Human und Maus zu detektieren.
Titration of the PARK8 antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 1:1000,Immunofluorescence: 1:10-1:50
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Buffer
In 1X PBS, pH 7.4, with 0.09 % sodium azide
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C
Informationen zur Lagerung
Aliquot the PARK8 antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.
Target
LRRK2
(Leucine-Rich Repeat Kinase 2 (LRRK2))
Andere Bezeichnung
PARK8
Hintergrund
Parkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson's disease identified to date. LRRK2/PARK8, a genetic mutation, was recently found linked to about 5 percent of inherited cases of Parkinson's disease. By high-resolution recombination mapping and candidate gene sequencing in 46 families, 6 disease-segregating mutations (5 missense and 1 putative splice site mutation). It may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism. PARK8 belongs to the ROCO protein family and includes a protein kinase domain of the MAPKKK class and several other major functional domains.